Drug Trial Radar · NCT07676175
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jan 31, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- BeBetter Med IncIndustry
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen University Cancer Center; First Affiliated Hospital Xi'an Jiaotong University
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to find the best way to combine the study drug BEBT-908 (ifupinostat hydrochloride for injection) with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for treating previously untreated peripheral T-cell lymphoma, and to find out whether this best combination is better than standard CHOP treatment alone. The main questions this study will try to answer are: What percentage of participants will respond well to treatment with BEBT-908 plus CHOP? Is BEBT-908 plus CHOP better than standard CHOP treatment? What medical problems will participants have while receiving this combination treatment? This study includes an Exploration Phase and an Expansion Phase. The Exploration Phase has 3 cohorts. All participants receive both BEBT-908 and CHOP, but the dosing arrangements differ across cohorts: the dose of BEBT-908 differs, the sequencing of administration differs, and whether participants continue with CHOP or transition to BEBT-908 depends on their tolerability to CHOP. Eligible participants will receive the combination treatment for their assigned cohort. After that, based on the results from all 3 cohorts in the Exploration Phase, one optimal cohort will be selected to proceed into the Expansion Phase. In the Expansion Phase, eligible participants will be randomly assigned (like flipping a coin) in a 1:1 ratio to either the treatment group, receiving the optimal combination regimen identified in the Exploration Phase, or the control group, receiving 6 cycles of CHOP. This study design will help investigators find the best way to combine BEBT-908 and CHOP for treating previously untreated peripheral T-cell lymphoma, and check whether this optimal combination regimen is better than standard CHOP treatment.
Conditions
- Previously Untreated Peripheral T-Cell Lymphoma
Interventions
Ifupinostat Hydrochloride for InjectionDrug
Administered by intravenous infusion at a dose of 8.2 mg/m² or 18.5 mg/m². It is administered on days 1, 3, 5, 8, 10, and 12 of each cycle. Each cycle lasts 21 days.
Cyclophosphamide for InjectionDrug
Administered by intravenous infusion at a dose of 750 mg/m². It is administered on day 1 of each cycle. Each cycle lasts 21 days.
Doxorubicin Hydrochloride for InjectionDrug
Administered by intravenous infusion at a dose of 50 mg/m². It is administered on day 1 of each cycle. Each cycle lasts 21 days.
Vincristine Sulfate for InjectionDrug
Administered by intravenous infusion at a dose of 1.4 mg/m² (maximum dose of 2 mg). It is administered on day 1 of each cycle. Each cycle lasts 21 days.
Prednisone Acetate TabletsDrug
Administered by mouth at a dose of 100 mg. It is administered on days 1 through 5 of each cycle. Each cycle lasts 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.